GSK, Moderna settle patent fight over COVID-19 and RSV vaccines without payments
GSK and Moderna settled their patent dispute over COVID-19 and RSV vaccine technology without payments. The agreement allows both to use each other's patented technologies. GSK sued Moderna in 2024, alleging patent infringement. The settlement covers Moderna's Spikevax, mNEXSPIKE, and mResvia vaccines. Both companies requested dismissal of GSK's US claims. This resolves one of several legal battles among pharmaceutical companies over COVID-19 vaccine technology.
How this was made
The 30-second read
Why it matters
Both companies remove a significant legal cloud, which could stabilize their stock prices and support ongoing vaccine sales.
Market read
The settlement is a primary corporate event for GSK and Moderna, offering a modest trade catalyst by eliminating litigation risk.
What to watch
Future licensing fees or royalty arrangements were not disclosed and could affect long‑term profitability.
Background
The article reports the first public disclosure of a cross‑licensing settlement between GSK and Moderna, ending a multi‑year patent fight over lipid‑nanoparticle technology used in COVID‑19 and RSV vaccines.
Ticker impact
GSK settled its patent dispute with Moderna, ending litigation in the US and Europe without any payment.
likely modest upside as risk premium is removed
The cross‑licensing settlement eliminates a pending lawsuit, which should ease investor concerns and support the stock.
Moderna reached a cross‑licensing settlement with GSK, allowing use of each other's patented technologies for its COVID‑19 and RSV vaccines.
likely modest upside as litigation risk is removed
With the dispute resolved, investors may view Moderna more favorably, though no cash changes hands.
Market effects
Reduces legal risk for the broader vaccine and mRNA technology sector.
Minimal immediate impact on UK or US markets beyond the two stocks.
Limited; primarily relevant to investors in GSK and Moderna.
Counterpoint
The settlement may signal deeper collaboration, potentially leading to joint ventures that could dilute competitive advantage.
Key entities
- companyGSK
British pharmaceutical firm involved in the settlement.
- companyModerna
US mRNA vaccine maker involved in the settlement.
